A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.

A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.

Zhitong Finance14:42

S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?

The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ

Benzinga01:04

Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $110

Jefferies analyst Roger Song maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 29.1% and

Futu NewsJul 3 20:31 · Ratings

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)

TipRanksJul 3 20:11

Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 33.85% on an annualized basis producing an average annual return of 46.66%. Currently, Viking Therapeutics has a

BenzingaJul 2 02:00

Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95

Stifel analyst Annabel Samimy maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.2% and

Futu NewsJul 1 21:31 · Ratings